{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:09:43Z","timestamp":1792404583642,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Transthyretin amyloid cardiomyopathy (ATTR-CM) is a frequent concomitant condition in patients with severe aortic stenosis (AS), yet it often remains undetected. This study aims to comprehensively evaluate artificial intelligence-based models developed based on preprocedural and routinely collected data to detect ATTR-CM in patients with severe AS planned for transcatheter aortic valve implantation (TAVI).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this prospective, single-center study, consecutive patients with AS were screened with [<jats:sup>99m<\/jats:sup>Tc]-3,3-diphosphono-1,2-propanodicarboxylic acid ([<jats:sup>99m<\/jats:sup>Tc]-DPD) for the presence of ATTR-CM. Clinical, laboratory, electrocardiogram, echocardiography, invasive measurements, 4-dimensional cardiac CT (4D-CCT) strain data, and CT-radiomic features were used for machine learning modeling of ATTR-CM detection and for outcome prediction. Feature selection and classifier algorithms were applied in single- and multi-modality classification scenarios. We split the dataset into training (70%) and testing (30%) samples. Performance was assessed using various metrics across 100 random seeds.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Out of 263 patients with severe AS (57% males, age 83\u2009\u00b1\u20094.6years) enrolled, ATTR-CM was confirmed in 27 (10.3%). The lowest performances for detection of concomitant ATTR-CM were observed in invasive measurements and ECG data with area under the curve (AUC)\u2009&lt;\u20090.68. Individual clinical, laboratory, interventional imaging, and CT-radiomics-based features showed moderate performances (AUC 0.70\u20130.76, sensitivity 0.79\u20130.82, specificity 0.63\u20130.72), echocardiography demonstrated good performance (AUC 0.79, sensitivity 0.80, specificity 0.78), and 4D-CT-strain showed the highest performance (AUC 0.85, sensitivity 0.90, specificity 0.74). The multi-modality model (AUC 0.84, sensitivity 0.87, specificity 0.76) did not outperform the model performance based on 4D-CT-strain only data (p-value\u2009&gt;\u20090.05). The multi-modality model adequately discriminated low and high-risk individuals for all-cause mortality at a mean follow-up of 13 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Artificial intelligence-based models using collected pre-TAVI evaluation data can effectively detect ATTR-CM in patients with severe AS, offering an alternative diagnostic strategy to scintigraphy and myocardial biopsy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00259-024-06922-4","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T03:09:35Z","timestamp":1727060975000},"page":"485-500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Multi-modality artificial intelligence-based transthyretin amyloid cardiomyopathy detection in patients with severe aortic stenosis"],"prefix":"10.1007","volume":"52","author":[{"given":"Isaac","family":"Shiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Balzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Baj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Bernhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Hundertmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bakula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Nakase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daijiro","family":"Tomii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Barbati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Dobner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldo","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Rominger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Caobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George C. M.","family":"Siontis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Lanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pilgrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Stortecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Gr\u00e4ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"6922_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jcmg.2023.10.010","volume":"17","author":"L Alwan","year":"2024","unstructured":"Alwan L, Benz DC, Cuddy SAM, Dobner S, Shiri I, Caobelli F, et al. Current and evolving Multimodality Cardiac Imaging in managing transthyretin amyloid cardiomyopathy. JACC Cardiovasc Imaging. 2024;17:195\u2013211. https:\/\/doi.org\/10.1016\/j.jcmg.2023.10.010.","journal-title":"JACC Cardiovasc Imaging"},{"key":"6922_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/ehjdh\/ztae022","author":"M Pereyra Pietri","year":"2024","unstructured":"Pereyra Pietri M, Farina JM, Mahmoud AK, Scalia IG, Galasso F, Killian ME, et al. The prognostic value of artificial intelligence to predict cardiac amyloidosis in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J - Digit Health. 2024. https:\/\/doi.org\/10.1093\/ehjdh\/ztae022.","journal-title":"Eur Heart J - Digit Health"},{"key":"6922_CR3","doi-asserted-by":"publisher","first-page":"E128","DOI":"10.1093\/eurheartj\/suab107","volume":"23","author":"G Fabbri","year":"2021","unstructured":"Fabbri G, Serenelli M, Cantone A, Sanguettoli F, Rapezzi C. Transthyretin amyloidosis in aortic stenosis: clinical and therapeutic implications. Eur Heart J Supplements. 2021;23:E128\u201332. https:\/\/doi.org\/10.1093\/eurheartj\/suab107.","journal-title":"Eur Heart J Supplements"},{"key":"6922_CR4","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","volume":"38","author":"A Casta\u00f1o","year":"2017","unstructured":"Casta\u00f1o A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38:2879\u201387. https:\/\/doi.org\/10.1093\/eurheartj\/ehx350.","journal-title":"Eur Heart J"},{"key":"6922_CR5","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","volume":"77","author":"C Nitsche","year":"2021","unstructured":"Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, et al. Prevalence and outcomes of concomitant aortic stenosis and Cardiac Amyloidosis. J Am Coll Cardiol. 2021;77:128\u201339. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.006.","journal-title":"J Am Coll Cardiol"},{"key":"6922_CR6","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.jacc.2019.09.056","volume":"74","author":"J Ternacle","year":"2019","unstructured":"Ternacle J, Krapf L, Mohty D, Magne J, Nguyen A, Galat A, et al. Aortic stenosis and Cardiac Amyloidosis: JACC Review topic of the Week. J Am Coll Cardiol. 2019;74:2638\u201351. https:\/\/doi.org\/10.1016\/j.jacc.2019.09.056.","journal-title":"J Am Coll Cardiol"},{"key":"6922_CR7","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1007\/s00259-023-06374-2","volume":"50","author":"B Abadie","year":"2023","unstructured":"Abadie B, Ali AH, Martyn T, Higgins A, Krishnaswamy A, Reed G, et al. Prevalence of ATTR-CA and high-risk features to guide testing in patients referred for TAVR. Eur J Nucl Med Mol Imaging. 2023;50:3910\u20136. https:\/\/doi.org\/10.1007\/s00259-023-06374-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6922_CR8","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial diseases. Eur Heart J. 2021;42:1554\u201368. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072.","journal-title":"Eur Heart J"},{"key":"6922_CR9","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/cir.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac amyloidosis: evolving diagnosis and management: a Scientific Statement from the American Heart Association. Circulation. 2020;142:e7\u201322. https:\/\/doi.org\/10.1161\/cir.0000000000000792.","journal-title":"Circulation"},{"key":"6922_CR10","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, et al. 2023 ACC Expert Consensus decision pathway on Comprehensive Multidisciplinary Care for the patient with Cardiac Amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81:1076\u2013126. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.022.","journal-title":"J Am Coll Cardiol"},{"key":"6922_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10554-020-01948-9","volume":"37","author":"K Rausch","year":"2021","unstructured":"Rausch K, Scalia GM, Sato K, Edwards N, Lam AK-y, Platts DG, Chan J. Left atrial strain imaging differentiates cardiac amyloidosis and hypertensive heart disease. Int J Cardiovasc Imaging. 2021;37:81\u201390. https:\/\/doi.org\/10.1007\/s10554-020-01948-9.","journal-title":"Int J Cardiovasc Imaging"},{"key":"6922_CR12","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s10554-020-02059-1","volume":"37","author":"JA Slivnick","year":"2021","unstructured":"Slivnick JA, Wallner AL, Vallakati A, Truong VT, Mazur W, Elamin MB, et al. Indexed left ventricular mass to QRS voltage ratio is associated with heart failure hospitalizations in patients with cardiac amyloidosis. Int J Cardiovasc Imaging. 2021;37:1043\u201351. https:\/\/doi.org\/10.1007\/s10554-020-02059-1.","journal-title":"Int J Cardiovasc Imaging"},{"key":"6922_CR13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s10554-023-02987-8","volume":"40","author":"M del Carmen Mall\u00f3n Araujo","year":"2024","unstructured":"del Carmen Mall\u00f3n Araujo M, Casas EAJ, Casas CAJ, Monzonis MAM, Morell \u00c1R, N\u00fa\u00f1ez VP. Cardiac scintigraphy and echocardiography assessment in the diagnosis of transthyretin cardiac amyloidosis. Int J Cardiovasc Imaging. 2024;40:415\u201324. https:\/\/doi.org\/10.1007\/s10554-023-02987-8.","journal-title":"Int J Cardiovasc Imaging"},{"key":"6922_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00259-023-06381-3","volume":"51","author":"HSA Tingen","year":"2023","unstructured":"Tingen HSA, Tubben A, van \u2019t Oever JH, Pastoor EM, van Zon PPA, Nienhuis HLA, et al. Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: a systematic review. Eur J Nucl Med Mol Imaging. 2023;51:93\u2013109. https:\/\/doi.org\/10.1007\/s00259-023-06381-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6922_CR15","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s10554-023-02840-y","volume":"39","author":"MC Navarro-Saez","year":"2023","unstructured":"Navarro-Saez MC, Feijoo-Mass\u00f3 C, Bravo Ferrer ZdC, Oliva Morera JC, Balado Gonz\u00e1lez AM, Palau-Dom\u00ednguez A, et al. Trends in diagnosis of cardiac transthyretin amyloidosis: 3-year analysis of scintigraphic studies: prevalence of myocardial uptake and its predictor factors. Int J Cardiovasc Imaging. 2023;39:1397\u2013404. https:\/\/doi.org\/10.1007\/s10554-023-02840-y.","journal-title":"Int J Cardiovasc Imaging"},{"key":"6922_CR16","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10554-022-02762-1","volume":"39","author":"J Geers","year":"2023","unstructured":"Geers J, Luchian M-L, Motoc A, De Winter J, Roosens B, Bjerke M, et al. Prognostic value of left ventricular global constructive work in patients with cardiac amyloidosis. Int J Cardiovasc Imaging. 2023;39:585\u201393. https:\/\/doi.org\/10.1007\/s10554-022-02762-1.","journal-title":"Int J Cardiovasc Imaging"},{"key":"6922_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10554-022-02692-y","volume":"39","author":"CP Shen","year":"2023","unstructured":"Shen CP, Vanichsarn CT, Pandey AC, Billick K, Rubenson DS, Mohan RC, et al. Wild type cardiac amyloidosis: is it time to order a nuclear technetium pyrophosphate SPECT imaging study? Int J Cardiovasc Imaging. 2023;39:201\u20138. https:\/\/doi.org\/10.1007\/s10554-022-02692-y.","journal-title":"Int J Cardiovasc Imaging"},{"key":"6922_CR18","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1007\/s10554-022-02676-y","volume":"38","author":"N Coskun","year":"2022","unstructured":"Coskun N, Kartal MO, Erdogan AS, Tufekcioglu O, Ozdemir E. Tc-99m pyrophosphate scintigraphy for cardiac amyloidosis: concordance between planar and SPECT\/CT imaging. Int J Cardiovasc Imaging. 2022;38:2081\u20138. https:\/\/doi.org\/10.1007\/s10554-022-02676-y.","journal-title":"Int J Cardiovasc Imaging"},{"key":"6922_CR19","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1007\/s10554-021-02190-7","volume":"37","author":"MF Santarelli","year":"2021","unstructured":"Santarelli MF, Genovesi D, Positano V, Scipioni M, Vergaro G, Favilli B, et al. Deep-learning-based cardiac amyloidosis classification from early acquired pet images. Int J Cardiovasc Imaging. 2021;37:2327\u201335. https:\/\/doi.org\/10.1007\/s10554-021-02190-7.","journal-title":"Int J Cardiovasc Imaging"},{"key":"6922_CR20","doi-asserted-by":"publisher","unstructured":"Allegra A, Mirabile G, Tonacci A, Genovese S, Pioggia G, Gangemi S. Machine learning approaches in diagnosis, prognosis and treatment selection of Cardiac Amyloidosis. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms24065680.","DOI":"10.3390\/ijms24065680"},{"key":"6922_CR21","doi-asserted-by":"publisher","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","volume":"385","author":"GS Collins","year":"2024","unstructured":"Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, et al. TRIPOD\u2009+\u2009AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. https:\/\/doi.org\/10.1136\/bmj-2023-078378.","journal-title":"BMJ"},{"key":"6922_CR22","doi-asserted-by":"publisher","first-page":"e030271","DOI":"10.1161\/jaha.123.030271","volume":"12","author":"S Dobner","year":"2023","unstructured":"Dobner S, Pilgrim T, Hagemeyer D, Heg D, Lanz J, Reusser N, et al. Amyloid transthyretin cardiomyopathy in Elderly patients with aortic stenosis undergoing transcatheter aortic valve implantation. J Am Heart Assoc. 2023;12:e030271. https:\/\/doi.org\/10.1161\/jaha.123.030271.","journal-title":"J Am Heart Assoc"},{"key":"6922_CR23","doi-asserted-by":"publisher","first-page":"e230425","DOI":"10.1148\/radiol.230425","volume":"309","author":"B Bernhard","year":"2023","unstructured":"Bernhard B, Leib Z, Dobner S, Demirel C, Caobelli F, Rominger A, et al. Routine 4D cardiac CT to identify concomitant transthyretin amyloid cardiomyopathy in older adults with severe aortic stenosis. Radiology. 2023;309:e230425. https:\/\/doi.org\/10.1148\/radiol.230425.","journal-title":"Radiology"},{"key":"6922_CR24","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.jacc.2012.09.001","volume":"60","author":"AP Kappetein","year":"2012","unstructured":"Kappetein AP, Head SJ, G\u00e9n\u00e9reux P, Piazza N, van Mieghem NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol. 2012;60:1438\u201354. https:\/\/doi.org\/10.1016\/j.jacc.2012.09.001.","journal-title":"J Am Coll Cardiol"},{"key":"6922_CR25","doi-asserted-by":"publisher","first-page":"e231319","DOI":"10.1148\/radiol.231319","volume":"310","author":"P Whybra","year":"2024","unstructured":"Whybra P, Zwanenburg A, Andrearczyk V, Schaer R, Apte AP, Ayotte A, et al. The image Biomarker Standardization Initiative: standardized Convolutional filters for reproducible Radiomics and enhanced clinical insights. Radiology. 2024;310:e231319. https:\/\/doi.org\/10.1148\/radiol.231319.","journal-title":"Radiology"},{"key":"6922_CR26","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1148\/radiol.2020191145","volume":"295","author":"A Zwanenburg","year":"2020","unstructured":"Zwanenburg A, Valli\u00e8res M, Abdalah MA, Aerts H, Andrearczyk V, Apte A, et al. The image Biomarker Standardization Initiative: standardized quantitative Radiomics for High-Throughput Image-based phenotyping. Radiology. 2020;295:328\u201338. https:\/\/doi.org\/10.1148\/radiol.2020191145.","journal-title":"Radiology"},{"key":"6922_CR27","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1158\/0008-5472.Can-17-0339","volume":"77","author":"JJM van Griethuysen","year":"2017","unstructured":"van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational Radiomics System to Decode the Radiographic phenotype. Cancer Res. 2017;77:e104\u20137. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-0339.","journal-title":"Cancer Res"},{"key":"6922_CR28","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: machine learning in Python. J Mach Learn Res. 2011;12:2825\u201330.","journal-title":"J Mach Learn Res"},{"key":"6922_CR29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266926","author":"F Caobelli","year":"2024","unstructured":"Caobelli F, G\u00f6zl\u00fcg\u00f6l N, Bakula A, Rominger A, Schepers R, Stortecky S, et al. Prognostic value of [(99m)tc]Tc-DPD quantitative SPECT\/CT in patients with suspected and confirmed amyloid transthyretin-related cardiomyopathy and preserved left ventricular function. J Nucl Med. 2024. https:\/\/doi.org\/10.2967\/jnumed.123.266926.","journal-title":"J Nucl Med"},{"key":"6922_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s10554-024-03148-1","author":"C Gr\u00e4ni","year":"2024","unstructured":"Gr\u00e4ni C. Early detection of subclinical cardiac amyloidosis: the importance of increasing physician awareness and routine imaging assessment. Int J Cardiovasc Imaging. 2024. https:\/\/doi.org\/10.1007\/s10554-024-03148-1.","journal-title":"Int J Cardiovasc Imaging"},{"key":"6922_CR31","doi-asserted-by":"publisher","first-page":"e016898","DOI":"10.1161\/circimaging.124.016898","volume":"17","author":"C Gr\u00e4ni","year":"2024","unstructured":"Gr\u00e4ni C. Advancements in CT tissue characterization: myocardial insights in aortic stenosis and amyloidosis. Circ Cardiovasc Imaging. 2024;17:e016898. https:\/\/doi.org\/10.1161\/circimaging.124.016898.","journal-title":"Circ Cardiovasc Imaging"},{"key":"6922_CR32","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1161\/circulationaha.118.034338","volume":"138","author":"J Zhang","year":"2018","unstructured":"Zhang J, Gajjala S, Agrawal P, Tison GH, Hallock LA, Beussink-Nelson L, et al. Fully automated Echocardiogram Interpretation in Clinical Practice. Circulation. 2018;138:1623\u201335. https:\/\/doi.org\/10.1161\/circulationaha.118.034338.","journal-title":"Circulation"},{"key":"6922_CR33","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1038\/s41467-021-22877-8","volume":"12","author":"S Goto","year":"2021","unstructured":"Goto S, Mahara K, Beussink-Nelson L, Ikura H, Katsumata Y, Endo J, et al. Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms. Nat Commun. 2021;12:2726. https:\/\/doi.org\/10.1038\/s41467-021-22877-8.","journal-title":"Nat Commun"},{"key":"6922_CR34","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1038\/s41467-021-22876-9","volume":"12","author":"A Huda","year":"2021","unstructured":"Huda A, Casta\u00f1o A, Niyogi A, Schumacher J, Stewart M, Bruno M, et al. A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy. Nat Commun. 2021;12:2725. https:\/\/doi.org\/10.1038\/s41467-021-22876-9.","journal-title":"Nat Commun"},{"key":"6922_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jclinepi.2014.09.007","volume":"68","author":"GC Siontis","year":"2015","unstructured":"Siontis GC, Tzoulaki I, Castaldi PJ, Ioannidis JP. External validation of new risk prediction models is infrequent and reveals worse prognostic discrimination. J Clin Epidemiol. 2015;68:25\u201334. https:\/\/doi.org\/10.1016\/j.jclinepi.2014.09.007.","journal-title":"J Clin Epidemiol"},{"key":"6922_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13550-022-00897-9","volume":"12","author":"HL Halme","year":"2022","unstructured":"Halme HL, Ihalainen T, Suomalainen O, Loimaala A, M\u00e4tzke S, Uusitalo V, et al. Convolutional neural networks for detection of transthyretin amyloidosis in 2D scintigraphy images. EJNMMI Res. 2022;12:27. https:\/\/doi.org\/10.1186\/s13550-022-00897-9.","journal-title":"EJNMMI Res"},{"key":"6922_CR37","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jcmg.2023.01.014","volume":"16","author":"MA Delbarre","year":"2023","unstructured":"Delbarre MA, Girardon F, Roquette L, Blanc-Durand P, Hubaut MA, Hachulla \u00c9, et al. Deep learning on bone scintigraphy to detect abnormal Cardiac Uptake at Risk of Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2023;16:1085\u201395. https:\/\/doi.org\/10.1016\/j.jcmg.2023.01.014.","journal-title":"JACC Cardiovasc Imaging"},{"key":"6922_CR38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12968-020-00690-4","volume":"22","author":"N Martini","year":"2020","unstructured":"Martini N, Aimo A, Barison A, Della Latta D, Vergaro G, Aquaro GD, et al. Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2020;22:84. https:\/\/doi.org\/10.1186\/s12968-020-00690-4.","journal-title":"J Cardiovasc Magn Reson"},{"key":"6922_CR39","doi-asserted-by":"publisher","unstructured":"Agibetov A, Kammerlander A, Duca F, Nitsche C, Koschutnik M, Don\u00e0 C, et al. Convolutional neural networks for fully automated diagnosis of Cardiac Amyloidosis by Cardiac magnetic resonance imaging. J Pers Med. 2021;11. https:\/\/doi.org\/10.3390\/jpm11121268.","DOI":"10.3390\/jpm11121268"},{"key":"6922_CR40","doi-asserted-by":"publisher","first-page":"1193046","DOI":"10.3389\/fradi.2023.1193046","volume":"3","author":"F Lo Iacono","year":"2023","unstructured":"Lo Iacono F, Maragna R, Pontone G, Corino VDA. A robust radiomic-based machine learning approach to detect cardiac amyloidosis using cardiac computed tomography. Front Radiol. 2023;3:1193046. https:\/\/doi.org\/10.3389\/fradi.2023.1193046.","journal-title":"Front Radiol"},{"key":"6922_CR41","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jcct.2023.04.002","volume":"17","author":"F Lo Iacono","year":"2023","unstructured":"Lo Iacono F, Maragna R, Guglielmo M, Chiesa M, Fusini L, Annoni A, et al. Identification of subclinical cardiac amyloidosis in aortic stenosis patients undergoing transaortic valve replacement using radiomic analysis of computed tomography myocardial texture. J Cardiovasc Comput Tomogr. 2023;17:286\u20138. https:\/\/doi.org\/10.1016\/j.jcct.2023.04.002.","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"6922_CR42","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585\u201394. https:\/\/doi.org\/10.1093\/eurheartj\/ehv338.","journal-title":"Eur Heart J"},{"key":"6922_CR43","doi-asserted-by":"publisher","unstructured":"Muller SA, Achten A, van der Meer MG, Zwetsloot PP, Sanders-van Wijk S, van der Harst P, et al. Absence of an increased wall thickness does not rule out cardiac amyloidosis. Amyloid. 2024;1\u20133. https:\/\/doi.org\/10.1080\/13506129.2024.2348681.","DOI":"10.1080\/13506129.2024.2348681"},{"key":"6922_CR44","doi-asserted-by":"publisher","first-page":"100538","DOI":"10.1016\/j.ejro.2023.100538","volume":"11","author":"A Donuru","year":"2023","unstructured":"Donuru A, Araki T, Dako F, Dave JK, Perez RP, Xu D, et al. Photon-counting detector CT allows significant reduction in radiation dose while maintaining image quality and noise on non-contrast chest CT. Eur J Radiol Open. 2023;11:100538. https:\/\/doi.org\/10.1016\/j.ejro.2023.100538.","journal-title":"Eur J Radiol Open"},{"key":"6922_CR45","doi-asserted-by":"publisher","unstructured":"Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC\/AHA Guideline for the management of patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines. Circulation. 2021;143:e35\u201371. https:\/\/doi.org\/10.1161\/cir.0000000000000932.","DOI":"10.1161\/cir.0000000000000932"},{"key":"6922_CR46","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1016\/s2589-7500(23)00265-0","volume":"6","author":"CP Spielvogel","year":"2024","unstructured":"Spielvogel CP, Haberl D, Mascherbauer K, Ning J, Kluge K, Traub-Weidinger T, et al. Diagnosis and prognosis of abnormal cardiac scintigraphy uptake suggestive of cardiac amyloidosis using artificial intelligence: a retrospective, international, multicentre, cross-tracer development and validation study. Lancet Digit Health. 2024;6:e251\u201360. https:\/\/doi.org\/10.1016\/s2589-7500(23)00265-0.","journal-title":"Lancet Digit Health"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06922-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06922-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06922-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T20:53:49Z","timestamp":1736888029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06922-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["6922"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06922-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standard of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study design was approved by the Bern cantonal ethics committee (ClinicalTrials.gov: NCT04061213), conducted in accordance with the Declaration of Helsinki, and study participants provided written informed consent before any data collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Dr. Bernhard reports a career development grant from the Swiss National Science Foundation. Dr. Pilgrim reports research grants to the institution from Biotronik, Boston Scientific and Edwards Lifesciences; speaker fees from Biotronik, Boston Scientific, Abbott, and Metronic; Clinical event committee for study sponsored by HighLifeSAS. Dr. Federico Caobelli reports ongoing Grants supports from Siemens Healthineers and from the University of Bern, as well as speaker honoraria from Bracco AG, Siemens AG and Pfizer AG, all for matters not related to the present study. Dr. Dobner reports a research grant for the Bern amyloidosis registry (B-CARE) (NCT04776824) and the ATTR Amyloidosis in Elderly Patients With Aortic Stenosis study (NCT04061213) on behalf of Inselspital Bern from Pfizer, and acknowledges speaker fees and travel grants unrelated to the submitted work from Boehringer Ingelheim, Alnylam and Pfizer. Dr. Windecker reports research, travel or educational grants to the institution from Abbott, Abiomed, Amgen, Astra Zeneca, Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardinal Health, CardioValve, Corflow Therapeutics, CSL Behring, Daiichi Sankyo, Edwards Lifesciences, Guerbet, InfraRedx, Janssen-Cilag, Johnson & Johnson, Medicure, Medtronic, Merck Sharp & Dohm, Miracor Medical, Novartis, Novo Nordisk, Organon, OrPha Suisse, Pfizer, Polares, Regeneron, Sanofi-Aventis, Servier, Sinomed, Terumo, Vifor, V-Wave. Dr. Windecker serves as advisory board member and\/or member of the steering\/executive group of trials funded by Abbott, Abiomed, Amgen, Astra Zeneca, Bayer, Boston Scientific, Biotronik, Bristol Myers Squibb, Edwards Lifesciences, Janssen, MedAlliance, Medtronic, Novartis, Polares, Recardio, Sinomed, Terumo, V-Wave and Xeltis with payments to the institution but no personal payments. He is also member of the steering\/executive committee group of several investigator-initiated trials that receive funding by industry without impact on his personal remuneration. Dr. Stortecky reports research grants to the institution from Edwards Lifesciences, Medtronic, Boston Scientific and Abbott, as well as personal fees from Boston Scientific, Teleflex and BTG. Dr. Gr\u00e4ni received research funding from the GAMBIT foundation for this work. Dr. Stortecky reports research grants to the institution from Edwards Lifesciences, Medtronic, Boston Scientific and Abbott, as well as personal fees from Boston Scientific, Teleflex and BTG. Dr. Gr\u00e4ni further received funding from the Swiss National Science Foundation and Innosuisse, from the Center for Artificial Intelligence in Medicine Research Project Fund University Bern, outside of the submitted work. Dr. Bakula reports speaker fees and travel grants from Pfizer. Dr. Shiri reports speaker fees and travel grants from Alnylam Pharmaceuticals. Dr. Rominger and Dr. Caobelli are editors of European Journal of Nuclear Medicine and Molecular Imaging. All other authors report no conflicts. The remaining authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}